Please note that maintenance work is scheduled between 4 AM and 5 AM - CET.
During this time, you may experience reduced performance.
Thanks for your patience.
in (world ranking)
Prof Federica Cavallo, PhD, MSc
Immunology — University of Turin, Italy
Federica Cavallo
Joined Sep 2026
University of Turin · Immunology
Top 1% Worldwide expert in Lymphoma, Lymphoproliferative Disorders
Top 1% Italy expert in Mammary Neoplasms, Animal, Nucleic Acid-Based Vaccines
An unblinded multi center study evaluating long term treatment with Zanubrutinib (BGB 3111) regimens in patients with blood cancer in the lymph node 2024-511267-28-00 — cells, blood, lymph nodes, neoplasms, multiple chronic conditions, lymph, therapeutics, b-lymphocytes
Phase 3
Active not recruiting
2021
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma 2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics
Phase 3
Active not recruiting
2021
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well Tolerated and How Well it Works Compared to Rituximab Combined with Chemotherapy for Adult Participants with Follicular Lymphoma 2022-502113-28-00 — lymphoma, follicular, safety, lymphoma, drug therapy, rituximab, chemotherapy
Phase 3
Recruiting
2024
Pilot phase II study of Selinexor in combination with Ifosfamide Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T cell Lymphomas 2024-513295-18-00 — cells, pilots, dexamethasone, ifosfamide, lymphoma, lymphoma, t-cell, peripheral, etoposide, t-lymphocytes, lymphoma, t-cell
Phase 2
Active not recruiting
2022
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B cells non Hodgkin Lymphoma 2023-506206-38-00 — cells, hodgkin disease, lymphoma, rituximab, geriatric assessment, lymphoma, non-hodgkin, therapeutics, b-lymphocytes
To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawal of consent may adversely affect certain features and functions.
Functional
Always active
Storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of transmitting a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
Storage or technical access used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles in order to send advertisements, or to track the user on a website or on several websites with similar marketing purposes.